

Quantum-Si Investor Presentation

Quantum-Si: Today's Speakers



John Stark
Chief Executive Officer



Claudia Drayton
Chief Financial Officer



Dr. Matthew Dyer
Chief Business Officer



Disclaimer

This presentation includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results of Quantum-Si Incorporated (the “Company”) may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company’s expectations with respect to future performance, development of products and services, potential regulatory approvals, the size and potential growth of current or future markets for the Company’s future products and services, or the Company’s plans expectations or future operations, financial position, revenues, costs or expenses. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the impact of COVID-19 on the Company’s business; the inability to maintain the listing of the Company’s shares of Class A common stock on The Nasdaq Stock Market; the ability to recognize the anticipated benefits of the Company’s recently-completed business combination, which may be affected by, among other things, competition and the ability of the Company to grow and manage growth profitably and retain its key employees; changes in applicable laws or regulations; the Company’s ability to raise financing in the future; the success, cost and timing of the Company’s product development activities; the potential attributes and benefits of the Company’s products and services; the Company’s ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company’s ability to identify, in-license or acquire additional technology; the Company’s ability to maintain its existing lease, license, manufacture and supply agreements; the Company’s ability to compete with other companies currently marketing or engaged in the development of products and services that the Company is developing; the size and growth potential of the markets for the Company’s future products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company’s products and services following anticipated commercial launch; the Company’s estimates regarding future expenses, future revenue, capital requirements and needs for additional financing; the Company’s financial performance; and other risks and uncertainties indicated from time to time in the Company’s filings with the U.S. Securities and Exchange Commission. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.



Driving the Forefront of Single Molecule Detection and Resolution

- Founded in 2013 and first to market Single Molecule Protein Sequencing End to End Benchtop System
- Extensive IP portfolio: >500 Issued and/or Pending Patents*
- >\$40B TAM: Expansion of Immune Understanding
- 5+ Early Access Systems active with External Sites
- Publicly Traded on the NASDAQ: QSI (June, 2021) raising \$500M+



*Over 100 issued patents and 450 pending patent applications across 125 patent families

The Next Transformation Anticipated in Life Sciences: Single Molecule Protein Sequencing

Genomics



Agilent Technologies

qPCR



Sanger



affymetrix

Microarrays



illumina®



life technologies™



PACBIO®



Oxford NANOPORE Technologies



ion torrent

Analog Gene and Transcript Resolution

Birth of Digital DNA Sequencing

Single Molecule, Benchtop Systems and Clinical

1990s

2000s

2010s - Current

Analog Protein and Peptide Level

Bench Top Single Molecule/Amino Acid Resolution



Mass Spec



BECKMAN COULTER

ELISA


Without legacy restrictions,
QSi has the opportunity to compete successfully




Protein

Why is understanding the Proteome transformative?


Proteins represent the clinical end point and building blocks of life



What is there?



How much is there?



How has it been changed?

Current State of Treatment

90% OF APPROVED DRUGS TARGET A PROTEIN¹

¹ The Human Proteome Tissue Atlas – Druggable Proteome, 2015, The Human Protein Atlas Project

Novel Therapies

85% OF PROTEOME UNDRUGGED²

² A Quest to Drug the Undruggable, June, Chemical & Engineering News, Volume 96, Issue 26, 2018

Patient Care

>100M IMMUNOASSAY TEST/YEAR³

³ "NPS Focus", Rainbow makers, Royal Society of Chemistry (RSC), 2003, retrieved 29 December 2012



The Next Generation Protein Sequencing Solution

Quantum-Si unique solution to enable absolute quantification and resolution of the Proteome

END-TO-END BENCHTOP SYSTEM

Decentralization by enabling the scientific and clinical community

TIME DOMAIN SEQUENCING™


Novel sequencing method that provides interrogation at the amino acid level

SINGLE MOLECULE RESOLUTION

Absolute measurement of unbiased biology providing novel insights into variant and structure modifications



End-to-End Protein Analysis Platform



Sample Prep

CARBON


Universal sample preparation for both protein and DNA.



Sequencing

PLATINUM

Scalable detection with single molecule sensitivity.



Analysis

CLOUD



Secure data storage and analysis workflows.



Delivering on What We Believe the Market Demands



	Mass Spec	Digital DNA Sequencing	Single Molecule DNA Sequencing	Quantum-Si
Quantitative Analysis (Protein)	✓	----	----	✓
Quantitative Analysis (DNA)	----	✓	✓	✓
Benchtop System	----	✓	----	✓
Single Molecule	----	----	✓	✓

Time Domain Sequencing™ provides amino acid resolution sequence of single peptides across millions of wells in parallel



Example trace from sequencing the Human GLP1 protein

Time Domain Sequencing™ Validated by External Sites






QUANTUM-SI CHIP LOADING




- 5+ global early access partners
- Data shown was generated by ESPCI on an early access Platinum device

Leveraging Early Access for Application Development

PEPTIDE-BARCODE HYBRID COMPLEXES



DUAL BARCODE AND PEPTIDE DYNAMIC RUNS



- Barcode development for sample multiplexing and future applications
- Collaboration with ESPCI and University of Wollongong

Novel Biological Understanding: Next Frontier of Assessing Recurrence and Treatment


Post-translational Modifications

Our technology detects post-translational modifications like any other amino acid. We can currently recognize phosphorylated tyrosine on chip and are working on other PTMs.

Pathways Activation

Tyrosine phosphorylation is a marker for pathway activation, e.g. how cells responds to drugs, infection.


Tyrosine



Phosphorylated Tyrosine



A



Estimated \$10B/Year Therapy Market Opportunity
EGFR/HER2 (Breast and Lung)

Potential Digital Disruption and Expansion of a \$44B Market

Quantitative Proteomics

\$31B (2020) 3% CAGR

Pharmaceutical and
diagnostic
development

>20,000

Proteomics Instrument
Installations

Sequencing

\$5B (2020) 8% CAGR

Basic Research,
Discovery and
Emerging Clinical
Application

>16,000

Bench Top DNA Digital
Sequencing Systems

Clinical Testing

\$8B (2020) 15% CAGR

Precision Medicine
Targeted Therapies

>132M


Molecular Tests Performed
Each Year in U.S

Data collected from SDI Global Report 2020 and Cowen Equity Research Life Science tools Kit 12th Edition.

Pathway for Growth and Customer Adoption

Status:

- ✓ Initiated early access
- ✓ Scaled production/supply chain
- ✓ Building commercial organization



By 2025:

> 5,000 units hardware

>\$45K annual pull through revenue/ device

Target gross margins > 70%

Pioneering Next Generation Single Molecule Sequencing



Company Core Focuses

1. Expansion of Product Development and Commercial Organization
2. Scale Product Readiness and Supply Chain
3. Expansion of Early Access Program Leading to Scaled Commercialization
4. Accelerate Single Molecule Applications and Future Products

Thank You



Meet the Team




**JONATHAN
ROTHBERG**

*Executive
Chairman*




**JOHN
STARK**

*Chief Executive
Officer*



**MIKE
MCKENNA**

*Chief Operations
Officer*




**CHRISTIAN
LAPOINTE**

*General
Counsel*



**CLAUDIA
DRAYTON**

*Chief Financial
Officer*




**MATT
DYER**

*Chief Business
Officer*



**GERARD
SCHMID**

*Head of Chip
Manufacturing*




**TODD
REARICK**

*Chief Technology
Officer*



**KIEREN
PATEL**

*Head of Product
and Marketing*



**BRIAN
REED**

*Head of
Research*



**FAISAL
AHMAD**

*Head of
Optical Devices*



**MEL
DAVEY**

*Head of
Software*



**MIKE
FERRIGNO**

*Head of
Hardware*



**LINDSAY
THOMPSON**

*Head of
People*

>140 Employees

